# Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

> **NCT00928330** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** GDC-0941
- **DRUG:** Trastuzumab
- **DRUG:** trastuzumab-MCC-DM1

## Key facts

- **NCT ID:** NCT00928330
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928330, "Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00928330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*